# Circular RNA UBAP2 contributes to tumor growth and metastasis of cervical cancer via modulating miR-361-3p/SOX4 axis.

- **DOI:** [10.1186/s12935-020-01436-z](https://doi.org/10.1186/s12935-020-01436-z)
- **Rating:** Limited (2.9 out of 5)
- **Verdict:** A competent ceRNA mechanism study that nominates circUBAP2 in cervical cancer, constrained by preliminary models and reporting inconsistencies.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-07-09
- **Evaluation page:** https://www.nabu.science/paper/10.1186%2Fs12935-020-01436-z

## Strengths

- **Layered evidence for proposed mechanism** The paper connects expression profiling, RNase R resistance, cytoplasmic localization, luciferase reporter assays, pull-down assays, and rescue experiments into a coherent circUBAP2/miR-361-3p/SOX4 mechanism. This provides more support than a descriptive expression-only study.
  - Dimension: methodological rigour
  - Location: Results Figs. 1, 3, 4, and 5
- **Functional rescue supports axis specificity** The rescue experiments test whether miR-361-3p inhibition or SOX4 overexpression reverses the effects of circUBAP2 knockdown on proliferation, apoptosis, migration, invasion, and EMT markers. This directly supports the proposed mechanistic chain in vitro.
  - Dimension: methodological rigour
  - Location: Results, CircUBAP2 deletion inhibits the CC cell progression in vitro via serving as a ceRNA; Fig. 5
- **In vivo experiments extend cell findings** The study goes beyond cell culture by testing sh-circUBAP2-transfected SiHa cells in subcutaneous tumor growth and tail-vein lung nodule models. These experiments provide preliminary in vivo support for growth and metastasis-related phenotypes.
  - Dimension: contribution
  - Location: Methods, Xenograft Experiments in Vivo; Results Fig. 6

## Limitations

- **Animal numbers are internally inconsistent** The Methods describe N=10 total mice, with 6 used for subcutaneous injection and another 4 for tail-vein metastasis, while the Results describe two groups of 5 mice for the tail-vein experiment. This weakens confidence in the in vivo metastasis reporting.
  - Dimension: methodological rigour
  - Location: Methods, Xenograft Experiments in Vivo; Results, CircUBAP2 promotes CC cell growth and metastasis in vivo
- **Clinical claims exceed survival reporting** The manuscript states that high circUBAP2 predicts poor outcome and frames circUBAP2 as a prognostic marker, but the survival analysis is based on 58 paired tissues and does not report group definition or covariate adjustment. The therapeutic-target framing is also based on genetic knockdown in preclinical models rather than a deployable intervention.
  - Dimension: application pathway
  - Location: Results Fig. 1c; Abstract; Conclusion
- **Model diversity limits generalizability** Functional work is performed in HeLa and SiHa cells, while C-33A is included in expression characterization but not in functional assays. This leaves HPV-negative or broader cervical-cancer contexts insufficiently tested.
  - Dimension: positioning
  - Location: Methods, Cell Culture; Results Figs. 1–6

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The main mechanistic narrative is coherent, but reporting inconsistencies and overextended prognostic or therapeutic language reduce confidence in precision. The most material issue is inconsistent mouse-number reporting for the in vivo metastasis experiment.
- **Research conduct:** Noted. Human and animal ethics approval and informed consent are declared, but approval identifiers are not provided and open-science transparency is minimal. No data availability, code availability, or reporting-standard declaration is evident in the supplied text.
- **Reference integrity:** Clean. All 35 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
